Similar studies were conducted to determine the effects of combined γ-tocotrienol treatment with PPARγ agonist rosiglitazone and troglitazone on PI3K/Akt mitogenic signaling in MCF-7 and MDA-MB-231 breast cancer cells. Here, AKT1 is linked to breast cancer.